Payment overview · 2025
General Payments
$266.29
12 reported records · 7 companies
Healthcare provider profile · identity verified
Charles A Slattery, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TITUSVILLE, FL · NPI 1821291048
Verified facts
What the public records show
CMS Open Payments records show Charles A Slattery, MD received $266.29 in general payments during 2025 across 12 reported records.
ViiV Healthcare Company accounted for 39.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Dovato, Farxiga, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $105.24 | 39.5% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $52.15 | 19.6% | 3 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $26.29 | 9.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.16 | 9.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.15 | 9.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.95 | 6.0% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $15.35 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $266.29 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $54.83 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.18 | 2 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $28.92 | 1 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $26.29 | 1 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $26.29 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $26.16 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| DOVATO dovato |
2025 | Dovato | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 185 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
185 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 329 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 273 | 76 |
| Ezetimibe | Ezetimibe | 248 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 225 | 55 |
| Atorvastatin Calcium | Atorvastatin Calcium | 220 | 62 |
| Omeprazole | Omeprazole | 218 | 59 |
| Simvastatin | Simvastatin | 195 | 59 |
| Farxiga | Dapagliflozin Propanediol | 185 | 47 |
| Gabapentin | Gabapentin | 183 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 180 | 54 |
| Montelukast Sodium | Montelukast Sodium | 167 | 51 |
| Carvedilol | Carvedilol | 143 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 140 | 43 |
| Losartan Potassium | Losartan Potassium | 138 | 38 |
| Alprazolam | Alprazolam | 134 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 34 |
| Metformin Hcl | Metformin Hcl | 123 | 34 |
| Dexamethasone | Dexamethasone | 115 | 69 |
| Duloxetine Hcl | Duloxetine Hcl | 115 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 25 |
| Allopurinol | Allopurinol | 97 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 96 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 90 | 27 |
| Ibandronate Sodium | Ibandronate Sodium | 88 | 36 |
| Jardiance | Empagliflozin | 88 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 13 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 73 | 13 |
| Meloxicam | Meloxicam | 70 | 21 |
| Sertraline Hcl | Sertraline Hcl | 70 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 22 |
| Azithromycin | Azithromycin | 62 | 48 |
| Furosemide | Furosemide | 60 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 18 |
| Buspirone Hcl | Buspirone Hcl | 58 | 16 |
| Juluca | Dolutegravir/Rilpivirine | 56 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 55 | suppressed |
| Atenolol | Atenolol | 53 | 15 |
| Clonazepam | Clonazepam | 50 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 34 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 45 | 14 |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 13 |
| Potassium Chloride | Potassium Chloride | 40 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Sucralfate | Sucralfate | 38 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Methocarbamol | Methocarbamol | 34 | 18 |
| Ozempic | Semaglutide | 34 | suppressed |
| Pifeltro | Doravirine | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 26 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 16 |
| Glimepiride | Glimepiride | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 16 |
| Eliquis | Apixaban | 21 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 14 |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Caplyta | Lumateperone Tosylate | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $266.29 · 12 records | ViiV Healthcare Company | AIRSUPRA, APRETUDE, CABENUVA, DOVATO, EGRIFTA, FARXIGA, MAVYRET, MOUNJARO, TROGARZO, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Dovato play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error